News

Sentinel Lymph Node Biopsy (SLNB) is the Gold Standard in Breast Cancer

The LEMKE Gamma Finder® II Provides Wireless SLN Detection and Ease of Use

It is known by oncologists and breast surgeons that removing multiple lymph nodes at the same time has been associated with adverse effects on breast cancer patients. For this reason, SLNB alone for staging breast cancer in women with no clinical signs of axillary lymph node metastasis, has become the gold standard of care.

The SLNB procedure is utilized in at least 65 % of breast cancer cases in the U.S. and EU, and just slightly lower in other countries. In the U.S. alone, approximately 253,000 cases of breast cancer will be diagnosed in 2017. There are many SLN detection devices on the market today, however, most are not completely handheld, wireless or convenient to use. What factors should be considered in selecting a gamma probe for SLNB? Of course high sensitivity, reliability and ease-of-use are important. The LEMKE Gamma Finder® II was developed with the surgeons in mind. Our handheld, wireless probe provides a clear display at your fingertips, audible sounds, an intuitive interface and high sensitivity for accurate detection of isotopes such as 99mTC. LEMKE is also regularly collecting surgeon feedback and gamma probe user insights to improve its devices such as the Gamma Finder® II.    

SLNB is most commonly used to help stage breast cancer and melanoma. However, this technology is being observed for other cancer types as well, including colorectal cancer, gastric cancer, esophageal cancer, head and neck cancer, thyroid cancer, and non-small cell lung cancer. The Gamma Finder® II has proven to be a valuable device across the globe.


Your LEMKE Team